Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Research Report 2025

Publication ID:

PB501253847

Publication Date:

January 15, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Viral Vectors and Plasmid DNA Manufacturing was valued at US$ 844 million in the year 2024 and is projected to reach a revised size of US$ 2649 million by 2031, growing at a CAGR of 18.0% during the forecast period.
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors and Plasmid DNA Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Segment by Type
Plasmid DNA
Viral Vectors
Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Plasmid DNA
1.2.3 Viral Vectors
1.3 麻豆原创 by Application
1.3.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Cancers
1.3.3 Inherited Disorders
1.3.4 Viral Infections
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Perspective (2020-2031)
2.2 Global Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region
2.2.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Dynamics
2.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
2.3.2 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Drivers
2.3.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Challenges
2.3.4 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue
3.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2020-2025)
3.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral Vectors and Plasmid DNA Manufacturing Revenue
3.4 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Concentration Ratio
3.4.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2024
3.5 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing Head office and Area Served
3.6 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing, Product and Application
3.7 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Type
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted 麻豆原创 Size by Type (2026-2031)
5 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Application
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size (2020-2031)
6.2 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2020-2025)
6.4 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size (2020-2031)
7.2 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2020-2025)
7.4 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size (2020-2031)
9.2 Latin America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioReliance
11.1.1 BioReliance Company Details
11.1.2 BioReliance Business Overview
11.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Introduction
11.1.4 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.1.5 BioReliance Recent Development
11.2 Cobra Biologics
11.2.1 Cobra Biologics Company Details
11.2.2 Cobra Biologics Business Overview
11.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Introduction
11.2.4 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.2.5 Cobra Biologics Recent Development
11.3 Oxford BioMedica
11.3.1 Oxford BioMedica Company Details
11.3.2 Oxford BioMedica Business Overview
11.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Introduction
11.3.4 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.3.5 Oxford BioMedica Recent Development
11.4 UniQure
11.4.1 UniQure Company Details
11.4.2 UniQure Business Overview
11.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Introduction
11.4.4 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.4.5 UniQure Recent Development
11.5 FinVector
11.5.1 FinVector Company Details
11.5.2 FinVector Business Overview
11.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Introduction
11.5.4 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.5.5 FinVector Recent Development
11.6 MolMed
11.6.1 MolMed Company Details
11.6.2 MolMed Business Overview
11.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Introduction
11.6.4 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.6.5 MolMed Recent Development
11.7 MassBiologics
11.7.1 MassBiologics Company Details
11.7.2 MassBiologics Business Overview
11.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Introduction
11.7.4 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.7.5 MassBiologics Recent Development
11.8 Richter-Helm
11.8.1 Richter-Helm Company Details
11.8.2 Richter-Helm Business Overview
11.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Introduction
11.8.4 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.8.5 Richter-Helm Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Details
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Lonza
11.10.1 Lonza Company Details
11.10.2 Lonza Business Overview
11.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Introduction
11.10.4 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.10.5 Lonza Recent Development
11.11 Aldevron
11.11.1 Aldevron Company Details
11.11.2 Aldevron Business Overview
11.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Introduction
11.11.4 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.11.5 Aldevron Recent Development
11.12 Eurogentec
11.12.1 Eurogentec Company Details
11.12.2 Eurogentec Business Overview
11.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Introduction
11.12.4 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.12.5 Eurogentec Recent Development
11.13 Cell and Gene Therapy Catapult
11.13.1 Cell and Gene Therapy Catapult Company Details
11.13.2 Cell and Gene Therapy Catapult Business Overview
11.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Introduction
11.13.4 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.13.5 Cell and Gene Therapy Catapult Recent Development
11.14 Biovian
11.14.1 Biovian Company Details
11.14.2 Biovian Business Overview
11.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Introduction
11.14.4 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.14.5 Biovian Recent Development
11.15 Thermo Fisher Scientific (Brammer Bio)
11.15.1 Thermo Fisher Scientific (Brammer Bio) Company Details
11.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
11.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Introduction
11.15.4 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Development
11.16 VGXI
11.16.1 VGXI Company Details
11.16.2 VGXI Business Overview
11.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Introduction
11.16.4 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.16.5 VGXI Recent Development
11.17 PlasmidFactory
11.17.1 PlasmidFactory Company Details
11.17.2 PlasmidFactory Business Overview
11.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Introduction
11.17.4 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2020-2025)
11.17.5 PlasmidFactory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.